Stoke Therapeutics Q3 2026 Earnings Date & Estimates

Stoke Therapeutics (NASDAQ:STOK) is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene. STK-001 is designed to restore productive SCN1A gene expression and increase production of functional sodium channel protein. The candidate has been evaluated in clinical studies involving children and adolescents with Dravet syndrome.

Founded in 2014 and headquartered in Bedford, Massachusetts, Stoke conducts research and development activities in the United States and works with clinical and research partners in support of its development programs. The company’s pipeline has also included additional investigational programs aimed at treating rare genetic diseases through targeted increases in gene expression.